Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infigratinib in infants and young children with achondroplasia
2024-518072-31-00Phase 2Authorised
- Sponsor
- QED Therapeutics
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of infigratinib in achondroplasia (ACH) (5 arms), sponsored by QED Therapeutics. Planned start Jan 2026; status: authorised.
02
Drugs
infigratinib
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on 2024-518072-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518072-31-00.